Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dominari Holdings Inc.SPEX · Entity 7162 | Director | February 16, 2018 | February 21, 2018 |
| Silo Pharma, Inc.SILO · Entity 8320 | Director · Chief Executive Officer | December 15, 2025 | December 16, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dominari Holdings Inc.
Report date February 16, 2018 · Filed February 21, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.0001 par value per shareSEC Table I · non-derivative | Direct | 20,000 |
Reported balance
After 2018-02-16 transaction · row 1
1 source rowRow 1 · 2018-02-16 · Grant · Acquired 20,000 · Balance 20,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.50 · Expires 2028-02-15 | Direct | 50,000 |
Reported balance
After 2018-02-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-02-16 · Grant · Acquired 50,000 · Balance 50,000 F1: 50% of the options vest on February 16, 2018 and the remaining 50% shall vest on August 16, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: 50% of the options vest on February 16, 2018 and the remaining 50% shall vest on August 16, 2018.
Silo Pharma, Inc.
Report date December 15, 2025 · Filed December 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 216,932 |
Ending reported balance
After 2025-12-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-12-15 · Purchase · Acquired 2,500 · Balance 214,432 Row 2 · 2025-12-15 · Purchase · Acquired 2,500 · Balance 216,932 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 15, 2025 Filed Dec 16, 2025 23:34 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 2,500 | $0.42 | $1,050.00 |
DisclosureSEC source: 0001213900-25-122429 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,932 Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 23:34 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 2,500 | $0.41 | $1,025.00 |
DisclosureSEC source: 0001213900-25-122429 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,432 Read SEC document |
| November 21, 2025 Filed Nov 21, 2025 23:35 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 1,000 | $0.37 | $365.00 |
DisclosureSEC source: 0001213900-25-113743 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,932 Read SEC document |
| November 20, 2025 Filed Nov 21, 2025 23:35 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 1,000 | $0.37 | $370.00 |
DisclosureSEC source: 0001213900-25-113743 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,932 Read SEC document |
| November 19, 2025 Filed Nov 20, 2025 21:00 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 4,500 | $0.41 | $1,822.50 |
DisclosureSEC source: 0001213900-25-113104 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,932 F2 · price: This price reflects the weighted average price at which these shares were purchased. The shares were purchased in multiple transactions on November 19, 2025 at prices ranging from $0.3975 to $0.4100. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 18, 2025 Filed Nov 20, 2025 21:00 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 7,500 | $0.40 | $3,024.75 |
DisclosureSEC source: 0001213900-25-113104 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,432 F1 · price: This price reflects the weighted average price at which these shares were purchased. The shares were purchased in multiple transactions on November 18, 2025 at prices ranging from $0.4000 to $0.4050. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 27, 2025 Filed May 28, 2025 20:30 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 10,000 | $0.43 | $4,329.00 |
DisclosureSEC source: 0001213900-25-048304 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,932 F1 · price: This price reflects the weighted average price at which these shares were purchased. The shares were purchased in multiple transactions at prices ranging from $0.42 to $0.45, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 23, 2025 Filed May 27, 2025 23:02 UTC | Silo Pharma, Inc. SILO · Entity 8320 | GrantOptions (right to buy) · Derivative | 200,000 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001213900-25-047912 · ownership.xml · derivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 387,932 Underlying: Common Stock · 200,000 shares Expires 2035-05-23 F1 · kind: The options were issued pursuant to the Issuer's 2020 Omnibus Equity Incentive Plan and one hundred percent (100%) of the shares subject to the option shall vest on the one (1)-year anniversary of the date of grant. Read SEC document |
| December 13, 2024 Filed Dec 16, 2024 22:00 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 2,500 | $0.84 | $2,096.75 |
DisclosureSEC source: 0001213900-24-109363 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,932 Read SEC document |
| November 22, 2024 Filed Nov 22, 2024 21:16 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 2,500 | $0.90 | $2,250.00 |
DisclosureSEC source: 0001213900-24-101610 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,432 Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 21:16 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 2,500 | $0.95 | $2,375.00 |
DisclosureSEC source: 0001213900-24-101610 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,932 Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 17:19 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 4,438 | $1.11 | $4,926.18 |
DisclosureSEC source: 0001213900-24-052354 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,432 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.11 to $1.12. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 17:19 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 562 | $1.08 | $606.96 |
DisclosureSEC source: 0001213900-24-052354 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,994 Read SEC document |
| April 05, 2024 Filed Apr 8, 2024 20:00 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 400 | $2.03 | $812.00 |
DisclosureSEC source: 0001213900-24-031159 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,432 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.00 to $2.05. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 20:00 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 600 | $1.96 | $1,176.00 |
DisclosureSEC source: 0001213900-24-031159 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,032 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.96 to $1.97. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 01, 2024 Filed Apr 1, 2024 22:15 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 1,100 | $1.91 | $2,101.00 |
DisclosureSEC source: 0001213900-24-028973 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,432 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.90 to $1.93. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 22:15 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 3,408 | $1.94 | $6,611.52 |
DisclosureSEC source: 0001213900-24-028973 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,332 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.91 to $1.95. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 20, 2023 Filed Dec 21, 2023 21:13 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 200 | $1.61 | $322.00 |
DisclosureSEC source: 0001213900-23-097689 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,924 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.60 to $1.63. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 19, 2023 Filed Dec 21, 2023 21:13 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 500 | $1.63 | $815.00 |
DisclosureSEC source: 0001213900-23-097689 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,724 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.61 to $1.65. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 00:44 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 900 | $1.52 | $1,368.00 |
DisclosureSEC source: 0001213900-23-096606 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,224 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.51 to $1.52. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 14, 2023 Filed Dec 19, 2023 00:44 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 200 | $1.50 | $300.00 |
DisclosureSEC source: 0001213900-23-096606 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,324 Read SEC document |
| December 07, 2023 Filed Dec 7, 2023 23:13 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 324 | $1.36 | $440.64 |
DisclosureSEC source: 0001213900-23-094145 · ownership.xml · nonDerivative · entry 3 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,124 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.34 to $1.40. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 06, 2023 Filed Dec 7, 2023 23:13 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 76 | $1.34 | $101.84 |
DisclosureSEC source: 0001213900-23-094145 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,800 Read SEC document |
| December 05, 2023 Filed Dec 7, 2023 23:13 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 600 | $1.39 | $834.00 |
DisclosureSEC source: 0001213900-23-094145 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,724 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.39 to $1.40. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 30, 2023 Filed Dec 1, 2023 02:10 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 1,000 | $1.53 | $1,530.00 |
DisclosureSEC source: 0001213900-23-091665 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,124 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.52 to $1.55. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 29, 2023 Filed Dec 1, 2023 02:10 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 1,000 | $1.57 | $1,570.00 |
DisclosureSEC source: 0001213900-23-091665 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,124 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.56 to $1.57. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 27, 2023 Filed Nov 27, 2023 22:13 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 250 | $1.78 | $445.00 |
DisclosureSEC source: 0001213900-23-090270 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,124 Read SEC document |
| November 22, 2023 Filed Nov 27, 2023 22:13 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 400 | $1.68 | $672.00 |
DisclosureSEC source: 0001213900-23-090270 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,874 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.64 to $1.70. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 21, 2023 Filed Nov 22, 2023 21:01 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 300 | $1.56 | $468.00 |
DisclosureSEC source: 0001213900-23-089570 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,474 Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 21:01 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 4,050 | $1.60 | $6,480.00 |
DisclosureSEC source: 0001213900-23-089570 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,174 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.57 to $1.65. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 17, 2023 Filed Nov 21, 2023 00:51 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 1,800 | $1.54 | $2,772.00 |
DisclosureSEC source: 0001213900-23-088890 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,124 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.45 to $1.60. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 16, 2023 Filed Nov 21, 2023 00:51 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 1,100 | $1.33 | $1,463.00 |
DisclosureSEC source: 0001213900-23-088890 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,324 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.24 to $1.46. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 18, 2023 Filed May 18, 2023 20:15 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 500 | $2.11 | $1,053.50 |
DisclosureSEC source: 0001213900-23-041179 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,724 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in two transactions at $2.104 and $2.109. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 17, 2023 Filed May 18, 2023 20:15 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 2,500 | $2.06 | $5,150.00 |
DisclosureSEC source: 0001213900-23-041179 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,224 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.000 to $2.0899. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 20, 2022 Filed Dec 21, 2022 00:07 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 130 | $2.72 | $353.60 |
DisclosureSEC source: 0001213900-22-081513 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,854 Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 00:07 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 200 | $2.68 | $536.30 |
DisclosureSEC source: 0001213900-22-081513 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,724 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.65 to $2.713. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 14, 2022 Filed Dec 15, 2022 21:15 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 263 | $3.17 | $833.68 |
DisclosureSEC source: 0001213900-22-080102 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,524 Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 21:15 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 487 | $3.07 | $1,493.92 |
DisclosureSEC source: 0001213900-22-080102 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,261 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.992 to $3.20. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 17, 2022 Filed Jun 21, 2022 12:05 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 13,080 | $0.11 | $1,500.28 |
DisclosureSEC source: 0001213900-22-033752 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CEO, CFO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,724,643 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.1302 to $0.11. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 18:31 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 17,500 | $0.14 | $2,409.75 |
DisclosureSEC source: 0001213900-21-065395 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,711,563 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.131 to $0.1455. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 10, 2021 Filed Dec 15, 2021 18:31 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 5,000 | $0.16 | $777.00 |
DisclosureSEC source: 0001213900-21-065395 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,694,063 Read SEC document |
| April 28, 2020 Filed May 17, 2021 11:33 UTC Amendment | Silo Pharma, Inc. SILO · Entity 8320 | GrantCommon Stock | 7,630,949 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-21-026677 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CEO, CFO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,689,063 F1 · price: Issued to the Reporting Person pursuant to that certain Employment Agreement, dated April 17, 2020, by and between the Issuer and the Reporting Person. F2 · balance_after: This Form 4 is being filed to amend the prior Form 4 filed by the Reporting Person on April 30, 2020, which erroneously included the Reporting Person's stock options in Column 5 of Table I. Read SEC document |
| April 17, 2020 Filed May 1, 2020 00:42 UTC | Silo Pharma, Inc. UCUT · Entity 8320 | GrantCommon Stock | 7,630,949 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-20-010688 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,988,663 F1 · price: Issued to Reporting Person pursuant to that certain Employment Agreement, dated April 17, 2020, between the Issuer and Reporting Person. Read SEC document |
| October 22, 2019 Filed May 17, 2021 11:31 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 200 | $0.45 | $90.00 |
DisclosureSEC source: 0001213900-21-026675 · ownership.xml · nonDerivative · entry 3 Weisblum Eric · CIK 0001569077 · Director · CEO, CFO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,114 Read SEC document |
| October 15, 2019 Filed May 17, 2021 11:31 UTC | Silo Pharma, Inc. SILO · Entity 8320 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-026675 · ownership.xml · derivative · entry 6 Weisblum Eric · CIK 0001569077 · Director · CEO, CFO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2024-10-15 Read SEC document |
| October 15, 2019 Filed May 17, 2021 11:31 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 200 | $0.38 | $76.00 |
DisclosureSEC source: 0001213900-21-026675 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · CEO, CFO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,914 Read SEC document |
| June 17, 2019 Filed May 17, 2021 11:31 UTC | Silo Pharma, Inc. SILO · Entity 8320 | PurchaseCommon Stock | 57,714 | $0.00 | $115.43 |
DisclosureSEC source: 0001213900-21-026675 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CEO, CFO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,714 Read SEC document |
| April 15, 2019 Filed May 17, 2021 11:31 UTC | Silo Pharma, Inc. SILO · Entity 8320 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-026675 · ownership.xml · derivative · entry 5 Weisblum Eric · CIK 0001569077 · Director · CEO, CFO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2024-07-15 F2 · date: The options were granted on April 15, 2019 and vested in full on July 15, 2019. F1 · price: The options were granted pursuant to the Employment Agreement by and between the Issuer and the Reporting Person dated April 15, 2019. F2 · derivative.exercise_date: The options were granted on April 15, 2019 and vested in full on July 15, 2019. Read SEC document |
| April 15, 2019 Filed May 17, 2021 11:31 UTC | Silo Pharma, Inc. SILO · Entity 8320 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-026675 · ownership.xml · derivative · entry 4 Weisblum Eric · CIK 0001569077 · Director · CEO, CFO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2024-04-15 F1 · price: The options were granted pursuant to the Employment Agreement by and between the Issuer and the Reporting Person dated April 15, 2019. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 00:44 UTC | Dominari Holdings Inc. SPEX · Entity 7162 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001615774-18-001339 · s109123_form4.xml · derivative · entry 2 Weisblum Eric · CIK 0001569077 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-02-15 F1 · derivative.exercise_date: 50% of the options vest on February 16, 2018 and the remaining 50% shall vest on August 16, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.